Literature DB >> 16569213

Angiotensin II stimulates phosphorylation of an ectodomain-truncated platelet-derived growth factor receptor-beta and its binding to class IA PI3K in vascular smooth muscle cells.

Ben-Bo Gao1, Hans Hansen, Hong-Chi Chen, Edward P Feener.   

Abstract

PI3K (phosphoinositide 3-kinase) activity is involved in Ang (angiotensin) II-stimulated VSMC (vascular smooth muscle cell) growth and hypertrophy. In the present study, we demonstrate that the inhibition of PI3K in VSMCs by expression of a dominant-negative p85alpha mutant lacking the p110-binding domain (Deltap85), or by treatment of cells with LY294002, inhibited Ang II-stimulated PAI-1 (plasminogen activator inhibitor-1) mRNA expression. Using a GST (glutathione S-transferase) fusion protein containing the p85 N-terminal SH2 (Src homology 2) domain as 'bait' followed by MS/MS (tandem MS), we identified a 70 kDa fragment of the p70 PDGFR-beta (platelet-derived growth factor receptor-beta) as a signalling adapter that is phosphorylated and recruits the p85 subunit of PI3K after Ang II stimulation of AT1 (Ang II subtype 1) receptors on VSMCs. This fragment of the PDGFR-beta, which has a truncation of its extracellular domain, accounted for approx. 15% of the total PDGFR-beta detected in VSMCs with an antibody against its cytoplasmic domain. Stimulation of VSMCs with Ang II increased tyrosine-phosphorylation of p70 PDGFR-beta at Tyr751 and Tyr1021 and increased its binding to p85. PDGF also induced phosphorylation of p70 PDGFR-beta, a response inhibited by the PDGF tyrosine kinase selective inhibitor, AG1296. By contrast, Ang II-induced phosphorylation of the 70 kDa receptor was not affected by AG1296. Ang II-stimulated phosphorylation of the p70 PDGFR-beta was blocked by the AT1 receptor antagonist, candesartan (CV 11974) and was partially inhibited by PP2 {4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine}, an Src family kinase inhibitor. Our result suggests that the p70 PDGFR-beta functions as an adapter that recruits PI3K to the membrane upon AT1 receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569213      PMCID: PMC1513282          DOI: 10.1042/BJ20060095

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

Review 1.  Plasminogen-activator inhibitor type 1 and coronary artery disease.

Authors:  H P Kohler; P J Grant
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

2.  Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc.

Authors:  S Heeneman; J Haendeler; Y Saito; M Ishida; B C Berk
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

3.  Akt is a major downstream target of PI3-kinase involved in angiotensin II-induced proliferation.

Authors:  Céline Dugourd; Marianne Gervais; Pierre Corvol; Catherine Monnot
Journal:  Hypertension       Date:  2003-03-03       Impact factor: 10.190

4.  Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.

Authors:  S Nakamura; I Nakamura; L Ma; D E Vaughan; A B Fogo
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

5.  Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression.

Authors:  H C Chen; J L Bouchie; A S Perez; A C Clermont; S Izumo; J Hampe; E P Feener
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-10       Impact factor: 8.311

6.  MEK1,2 response element mediates angiotensin II-stimulated plasminogen activator inhibitor-1 promoter activation.

Authors:  Hong-Chi Chen; Edward P Feener
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

7.  Transactivation of the insulin-like growth factor-I receptor by angiotensin II mediates downstream signaling from the angiotensin II type 1 receptor to phosphatidylinositol 3-kinase.

Authors:  Peter Zahradka; Brenda Litchie; Ben Storie; Gail Helwer
Journal:  Endocrinology       Date:  2004-02-19       Impact factor: 4.736

8.  ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells.

Authors:  Sassan Hafizi; Xuemin Wang; Adrian H Chester; Magdi H Yacoub; Christopher G Proud
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-09       Impact factor: 4.733

9.  DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease.

Authors:  Alexandre H Campos; Ying Zhao; Matthew J Pollman; Gary H Gibbons
Journal:  Circ Res       Date:  2003-01-10       Impact factor: 17.367

10.  SAM68: a downstream target of angiotensin II signaling in vascular smooth muscle cells in genetic hypertension.

Authors:  Mohammed El Mabrouk; Quy N Diep; Karim Benkirane; Rhian M Touyz; Ernesto L Schiffrin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-23       Impact factor: 4.733

View more
  9 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Connective tissue growth factor differentially binds to members of the cystine knot superfamily and potentiates platelet-derived growth factor-B signaling in rabbit corneal fibroblast cells.

Authors:  Liya Pi; Pei-Yu Chung; Sriniwas Sriram; Masmudur M Rahman; Wen-Yuan Song; Edward W Scott; Bryon E Petersen; Gregory S Schultz
Journal:  World J Biol Chem       Date:  2015-11-26

3.  Label-free quantitative analysis of one-dimensional PAGE LC/MS/MS proteome: application on angiotensin II-stimulated smooth muscle cells secretome.

Authors:  Ben-Bo Gao; Lisa Stuart; Edward P Feener
Journal:  Mol Cell Proteomics       Date:  2008-08-02       Impact factor: 5.911

4.  Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle.

Authors:  Eric B Taylor; Ding An; Henning F Kramer; Haiyan Yu; Nobuharu L Fujii; Katja S C Roeckl; Nicole Bowles; Michael F Hirshman; Jianxin Xie; Edward P Feener; Laurie J Goodyear
Journal:  J Biol Chem       Date:  2008-02-13       Impact factor: 5.157

5.  Identification of a novel phosphorylation site on TBC1D4 regulated by AMP-activated protein kinase in skeletal muscle.

Authors:  Jonas T Treebak; Eric B Taylor; Carol A Witczak; Ding An; Taro Toyoda; Ho-Jin Koh; Jianxin Xie; Edward P Feener; Jørgen F P Wojtaszewski; Michael F Hirshman; Laurie J Goodyear
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-18       Impact factor: 4.249

6.  Inhibition of phosphatidylinositol 3-kinase/Akt signaling attenuates hypoxia-induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cells.

Authors:  Chrystelle V Garat; Joseph T Crossno; Timothy M Sullivan; Jane E B Reusch; Dwight J Klemm
Journal:  J Cardiovasc Pharmacol       Date:  2013-12       Impact factor: 3.105

7.  CREB depletion in smooth muscle cells promotes medial thickening, adventitial fibrosis and elicits pulmonary hypertension.

Authors:  Chrystelle V Garat; Susan M Majka; Timothy M Sullivan; Joseph T Crossno; Jane E B Reusch; Dwight J Klemm
Journal:  Pulm Circ       Date:  2020-04-14       Impact factor: 2.886

8.  Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.

Authors:  Claudio Cabello-Verrugio; María Gabriela Morales; Daniel Cabrera; Carlos P Vio; Enrique Brandan
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

9.  LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome.

Authors:  Philippe Boucher; Wei-Ping Li; Rachel L Matz; Yoshiharu Takayama; Johan Auwerx; Richard G W Anderson; Joachim Herz
Journal:  PLoS One       Date:  2007-05-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.